Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus KETOTIFEN FUMARATE.
AZELASTINE HYDROCHLORIDE vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine hydrochloride is a phthalazinone derivative that exerts its effect by competitively inhibiting histamine at the H1 receptor site. It also stabilizes mast cells, reducing the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This dual action provides both antihistaminic and anti-inflammatory effects.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
1 spray (137 mcg) per nostril twice daily; ophthalmic: 1 drop in affected eye(s) twice daily.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 22 hours (range 20–25 hours) following oral administration, supporting twice-daily dosing. For ophthalmic and intranasal routes, systemic half-life is similar due to absorption.
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Approximately 75% of the dose is excreted in feces as unchanged drug and metabolites; about 25% is excreted renally, with less than 10% as unchanged drug.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category C
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer